Cargando…
Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway
Doxorubicin (DOX), an anthracycline type of chemotherapy, is an effective therapy for several types of cancer, but serious side effects, such as severe hepatotoxicity, limit its use currently. Accordingly, an effective therapeutic strategy to prevent DOX-related hepatotoxicity is urgently needed. Th...
Autores principales: | Xu, Xianchou, Liu, Qingbo, Li, Jiahao, Xiao, Mengjie, Gao, Ting, Zhang, Xiaohui, Lu, Guangping, Wang, Jie, Guo, Yuanfang, Wen, Peinan, Gu, Junlian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468578/ https://www.ncbi.nlm.nih.gov/pubmed/36110535 http://dx.doi.org/10.3389/fphar.2022.940406 |
Ejemplares similares
-
Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway
por: Lu, Guangping, et al.
Publicado: (2022) -
Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation
por: Xuan, Yue, et al.
Publicado: (2022) -
Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2
por: Wang(a), Jie, et al.
Publicado: (2022) -
A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity
por: Xiao, Mengjie, et al.
Publicado: (2021) -
p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act
por: Guo, Yuanfang, et al.
Publicado: (2023)